Aldeyra Therapeutics (ALDX) Misses Q3 EPS by 1c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.27), $0.01 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
• AppLovin drops 3% as Edgewater analyst warns of stalled market share growth